Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications

Biotechnology

Therapeutics

Anavo Therapeutics BV

Birgit Zech

Jacqueline Dreyer-Lamm

Gerhard Müller

The Leadership Team at Anavo Therapeutics BV is responsible for steering the company's strategic direction, driving scientific and operational excellence, and establishing key partnerships to advance Anavo's pioneering work in phosphatase-targeted therapies. Comprising the Chief Scientific Officer, CEO, SVP of Biology and Site Head Heidelberg, and SVP of Chemistry and Non-clinical Development, this team ensures the alignment of research, development, and business objectives to build a robust pipeline for oncology and other indications.

Leadership Team

About

Team members

Other teams at Anavo Therapeutics BV

Biology Team